CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...